[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Cvetković RS, Perry CM: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs; 2006;66(6):791-820
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
  • Rituximab (MabThera, Rituxan) is an anti-CD20 monoclonal antibody that induces lysis and apoptosis of normal and malignant human B cells, and sensitises malignant B cells to the cytotoxic effect of chemotherapy.
  • In phase III trials in patients with indolent or aggressive B-cell non-Hodgkin's lymphoma (NHL), intravenous rituximab in combination with chemotherapy was more effective as first- or second-line therapy than chemotherapy alone in providing tumour remission and patient survival.
  • Likewise, in patients with chronic lymphocytic leukaemia (CLL), rituximab in combination with chemotherapy appeared more effective than chemotherapy alone as either first- or second-line treatment.
  • In addition, rituximab maintenance therapy was shown to significantly prolong tumour remission and patient survival in patients with indolent B-cell NHL or CLL.
  • The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone.
  • Rituximab, either alone or in combination with chemotherapy, was generally well tolerated in patients with NHL or CLL.
  • Overall, rituximab in combination with chemotherapy, is a valuable option for first- and second-line therapy in patients with advanced-stage indolent or aggressive B-cell NHL, and possibly those with B-cell CLL, and is included in current treatment guidelines for these indications.
  • The drug is also potentially useful as maintenance therapy in patients with indolent B-cell NHL or CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / economics. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Drug Therapy, Combination. Humans. Meta-Analysis as Topic. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82 [15361313.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):139-46 [12867117.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61 [11226001.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7435-43 [17082663.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):520-35 [12649096.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):995-1001 [9818074.001]
  • [Cites] Ann Hematol. 2002 Oct;81(10):553-7 [12424535.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1392-8 [11222385.001]
  • [Cites] Br J Haematol. 2004 May;125(3):294-317 [15086411.001]
  • [Cites] J Radiat Res. 2005 Jun;46(2):241-8 [15988143.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] AIDS. 2003 Sep 5;17(13):2006-7 [12960844.001]
  • [Cites] Clin Lymphoma. 2004 Sep;5(2):81-3 [15453921.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5971-80 [16115941.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):705-11 [15598978.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):16-25 [15934514.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8114-27 [16103877.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):697-714; discussion 714, 717, 721 [9597680.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):44-8 [12670330.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3280-8 [14978136.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Drugs. 2003;63(8):803-43 [12662126.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2743-52 [16284990.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2741-5 [12842999.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1 Suppl 1):S4-10 [15786020.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1799-801 [11114321.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):7-15 [15934513.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Annu Rev Med. 2004;55:477-503 [14746532.001]
  • (PMID = 16706552.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 108
  •  go-up   go-down


2. Weide R, Heymanns J, Gores A, Köppler H: Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma; 2002 Feb;43(2):327-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bendamustine (B) and mitoxantrone (M) have been shown to be potent cytotoxic drugs for the treatment of relapsed or refractory indolent lymphomas.
  • This study was an open label, single center pilot study for patients with relapsed or refractory, CD20-positive (indolent) lymphoma or chronic lymphocytic leukaemia.
  • The therapy consisted of bendamustine (80 mg/m2, day 1-3), mitoxantrone (10 mg/m2, day 1), rituximab (375 mg/m2, week 2-5).
  • The maximum therapy consisted of one BMR-cycle, followed by five BM courses.
  • Treatment was stopped when the disease responded with PR/CR.
  • During March 1999 and December 2000, 20 patients received the BMR-regimen (four secondary high grade lymphoma, 12 indolent lymphoma, four B-CLL).
  • Median number of previous treatment regimens was two (1-6).
  • Of the lymphoma patients, 14 had stage IV disease, 1 stage III and 1 stage II.
  • B-CLL patients were all Rai stage IV (Binet C).
  • Overall response rate was 95% (19/20) with seven patients achieving a CR (35%) and 12 patients achieving a PR (60%).
  • Median time to progression is 7 months (1-21) with a median observation time of 7 months (1-21).
  • Response is still durable in 15/20 patients (75%) (1+ to 21+ months after therapy).
  • In conclusion, BMR is a well tolerated, very effective outpatient regimen of treatment for relapsed and refractory indolent lymphoid malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Disease-Free Survival. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Middle Aged. Mitoxantrone / administration & dosage. Nitrogen Mustard Compounds / administration & dosage. Remission Induction. Rituximab. Salvage Therapy

  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999564.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Nitrogen Mustard Compounds; 4F4X42SYQ6 / Rituximab; 981Y8SX18M / Bendamustine Hydrochloride; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


3. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol; 2001;40(2-3):135-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
  • This report by The Swedish Council on Technology Assessment in Health Care (SBU) reviews, classifies, and grades the scientific literature on cancer chemotherapy in some major tumour types, describes the practice of chemotherapy in Sweden, compares practice with scientific knowledge, and analyses the costs and cost-effectiveness of chemotherapy.
  • The report is intended primarily for decision-makers at various levels, both practitioners and administrators.
  • For the final evaluation to be as close to the objective truth as possible, a concerted effort was made to guarantee objectivity and thorough assessment of current knowledge about the effects of chemotherapy on the selected cancers.
  • The tumour types selected for this assessment include firstly those types where three investigations had shown an increased use of chemotherapy in Sweden during the latest decade.
  • Secondly, the two tumour types comprising the greatest number of patients treated with chemotherapy in Sweden, breast cancer and haematological malignancies, were included.
  • Among the haematological malignancies, the most prevalent ones, acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin's disease (HD), aggressive non-Hodgkin's lymphoma (NHL) of the large B-cell type and indolent NHL of follicular type were evaluated.
  • Thirdly, ovarian cancer was included since chemotherapy has been extensively used and since, at the time of the planning of this overview, a group of very expensive drugs, the taxanes, had preliminarily shown promising results.
  • A wealth of scientific literature has been published on cancer therapy.
  • The review presented in this report is limited to scientific studies judged to be important for evaluating chemotherapy efficacy.
  • The survey of practice of chemotherapy use involved all departments of surgery, urology, gynaecology, internal medicine including haematologic units, pulmonary medicine and general and gynaecologic oncology at 16 hospitals in two health care regions in Sweden, covering 39% of the Swedish population.
  • During the 4 weeks of the survey, all patients with the diagnoses concerned who received chemotherapy were registered.
  • The working group's general conclusions are summarised in the following points: The literature on the effects of chemotherapy is extensive.
  • Chemotherapy has a well-documented role in the curative and palliative treatment of patients with several types of cancer.
  • The use of chemotherapy is of utmost importance for the possibility of cure in certain tumour types.
  • In other tumours, chemotherapy increases the possibility of cure when added to local and regional treatments, particularly surgery.
  • In the instances of no possibility of cure, chemotherapy may to a variable extent improve both patient survival and well-being.
  • In Sweden chemotherapy is largely used in accordance with that documented in the scientific literature.
  • The extent of both over- and under-treatment seems to be limited but cannot be excluded at the individual patient level.
  • The literature-based knowledge is scientifically of lower quality in the most chemotherapy sensitive tumours than in tumours showing more limited sensitivity.
  • In the more sensitive tumours, positive effects on a symptomatic stage and survival were seen several decades ago.
  • In those days, clinical treatment studies did not fulfil the current high quality requirements.
  • Small life-prolonging effects of chemotherapy are sometimes very well documented in large, high quality scientific studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Technology Assessment, Biomedical
  • [MeSH-minor] Cost-Benefit Analysis. Decision Making. Drug Costs. Evidence-Based Medicine. Humans. Sweden

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441927.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


Advertisement
4. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE: CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol; 2008 Mar;140(5):537-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
  • In vitro studies have demonstrated that surface expression of CD49d on chronic lymphocytic leukaemia (CLL) B cells facilitates leukaemic cell-stromal interactions by binding to fibronectin.
  • This interaction reduces both spontaneous and drug-induced apoptosis.
  • The present study measured CD49d expression by flow cytometry in a cohort of untreated CLL patients previously accrued to a prospective observational study and evaluated the relationship with overall survival (OS).
  • Among the 158 CLL patients tested, the percentage of leukaemic B cells expressing CD49d ranged from 0 to 100%.
  • Multivariate analysis, controlling for disease stage, ZAP-70, IGHV status and fluorescent in situ hybridization defects identified CD49d as an independent predictor of OS and was a better predictor of clinical outcome than ZAP-70, IGHV, or cytogenetics.
  • This observational cohort study suggests that CLL B-cell expression of CD49d is an easily measurable and independent predictor of OS and CD49d expression in CLL.
  • Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases.
  • Clinical testing of anti-CD49d therapy in CLL appears warranted.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Future Oncol. 2008 Jun;4(3):355-8 [18518761.001]
  • (PMID = 18275431.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / CA 113408; United States / NCI NIH HHS / CA / K23 CA113408-01A1; None / None / / K23 CA113408-01A1; United States / NCI NIH HHS / CA / K07 CA094919; United States / NCI NIH HHS / CA / K23 CA113408-02; United States / NCI NIH HHS / CA / P50 CA097274; None / None / / K23 CA113408-02; United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / CA 94919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 143198-26-9 / Integrin alpha4
  • [Other-IDs] NLM/ NIHMS60638; NLM/ PMC4477272
  •  go-up   go-down


5. Kaiser U: Cerebral involvement as the initial manifestation of chronic lymphocytic leukaemia. Acta Haematol; 2003;109(4):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral involvement as the initial manifestation of chronic lymphocytic leukaemia.
  • Stereotactic biopsy revealed infiltration by lymphocytes compatible with the diagnosis of chronic lymphocytic leukaemia (CLL).
  • Simultaneously, Binet stage II CLL with bone marrow infiltration was diagnosed.
  • Cranial radiotherapy with 36 Gy was performed.
  • Cerebral involvement is rare but may occur in early CLL.
  • In case of spinal fluid involvement intrathecal chemotherapy is recommended.
  • [MeSH-major] Basal Ganglia / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemic Infiltration / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12853692.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E: Mycosis fungoides associated with B-cell malignancies. Br J Dermatol; 2006 Aug;155(2):379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Eleven patients with mycosis fungoides and B-cell malignancy were detected (seven of non-Hodgkin's lymphoma, three of chronic lymphocytic leukaemia, one of multiple myeloma).
  • The time elapsed between onset of the two malignancies ranged from 4 to 22 years (average: 12 years).
  • Among the four patients in whom the appearance of mycosis fungoides followed the B-cell malignancy, three had been treated with multiagent chemotherapy.
  • Two patients who presented with early-stage mycosis fungoides (IA) as the first lymphoma developed mycosis fungoides tumours after becoming immunosuppressed.
  • One showed two distinct populations of the malignant cells in the skin tumour, thus constituting a classical composite lymphoma of mycosis fungoides and chronic lymphocytic leukaemia, while in the other patient the two malignant populations of marginal B-cell lymphoma and mycosis fungoides (as evidenced by both phenotypic and genotypic findings) were intermingled.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Male. Middle Aged


7. Eisterer W, Bechter O, Söderberg O, Nilsson K, Terol M, Greil R, Thaler J, Herold M, Finke L, Günthert U, Montserrat E, Stauder R: Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res; 2004 Oct;28(10):1043-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
  • We evaluated the prognostic value of soluble CD44 in B-cell chronic lymphocytic leukaemia (B-CLL) and analysed the source and regulation of CD44 secretion in B-CLL clones in vitro.
  • Highly purified B-CLL cells (98% CD19 + CD3 - cells) were stimulated in vitro by different combinations of thioredoxin (Trx), Staphylococcus aureus Cowan strain 1 (SAC), IL-2, IL-4, IL-10, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and by anti-CD40 mAbs presented on irradiated CD32L cells.
  • RESULTS: Serum levels of sCD44s and of sCD44v6 are significantly elevated in B-CLL patients (n = 90) in comparison with normal persons (n = 44) (P < 0.001).
  • Elevated levels of sCD44s and sCD44v6 are associated with an advanced disease as reflected by an extended lymph node involvement (P < 0.02), an advanced Binet (P < 0.03) and Rai stage (P < 0.04) and chemotherapy requirement (P < 0.02).
  • In B-CLL sCD44s as well as sCD44v6 is shed from leukaemia cells as shown by in vitro cultures.
  • Stimulation of B-CLL clones results in a proliferation-associated increased secretion of sCD44s (rho = 0.7; P = 0.0001) and of sCD44v6 (rho = 0.5; P = 0.005).
  • B-CLL clones from advanced stage patients are characterised by an increased capacity for proliferation and CD44 production in comparison with early stage patients.
  • CONCLUSIONS: Both sCD44s and sCD44v6 represent a reliable prognostic marker in B-CLL and may be involved in the pathogenesis of B-CLL.
  • [MeSH-major] Antigens, CD44 / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocytes / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15289016.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 9007-49-2 / DNA
  •  go-up   go-down


8. Hewamana S, Pepper C, Jenkins C, Rowntree C: Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia. Clin Exp Nephrol; 2009 Apr;13(2):179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia.
  • Chronic lymphocytic leukaemia (CLL) is a neoplastic condition of B cells which commonly affects the lymph nodes, liver, spleen and bone marrow.
  • Leukaemic involvement of the kidney is also relatively common in CLL, but characteristically is not associated with renal impairment.
  • Our report describes a patient who developed acute renal failure as the initial presenting feature of CLL.
  • Treatment with chlorambucil and prednisolone resulted in stabilisation of the renal function for approximately 1 year prior to the need for long-term haemodialysis.
  • Leukaemic infiltration of kidney should always be considered when a patient with CLL presents with renal impairment, regardless of the clinical stage, as the renal failure often responds well to chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 May;12(5):432-40 [7250955.001]
  • [Cites] Rinsho Ketsueki. 2002 Nov;43(11):993-7 [12508485.001]
  • [Cites] Nephrol Dial Transplant. 2008 Feb;23(2):770-1 [17998226.001]
  • [Cites] Am J Med. 1988 Oct;85(4):579-80 [3177414.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Int J Clin Pract Suppl. 2005 Apr;(147):53-5 [15875623.001]
  • [Cites] Nephrol Dial Transplant. 1990;5(12):1051-2 [2128953.001]
  • [Cites] J Clin Pathol. 1993 Dec;46(12):1131-3 [8282840.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):827-37 [3474054.001]
  • [Cites] Gen Diagn Pathol. 1997 Feb;142(3-4):147-53 [9065578.001]
  • [Cites] Am J Med Sci. 1961 Apr;241:512-8 [13729602.001]
  • (PMID = 19255826.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kalil N, Cheson BD: Management of chronic lymphocytic leukaemia. Drugs Aging; 2000 Jan;16(1):9-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of chronic lymphocytic leukaemia.
  • Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in Western countries.
  • Cytogenetic abnormalities are frequent in patients with CLL, and may be associated with poor prognosis.
  • Aggressive transformation occurs in 10% of patients with CLL, most commonly prolymphocytic leukaemia (PLL) and Richter's syndrome.
  • PLL de novo must be differentiated from PLL of an aggressive transformation.
  • The incidences of autoimmune diseases and solid or haemopoietic secondary malignancies are increased in patients with CLL.
  • Clinical stage is the strongest prognostic factor in CLL.
  • The current recommendation to start treatment includes disease-related symptoms, massive and/or progressive hepatosplenomegaly or lymphadenopathy, increasing bone marrow failure, autoimmune disease, and recurrent infections.
  • Alkylating agents (e.g. chlorambucil) and nucleoside analogues (e.g. fludarabine) are the most active agents for CLL.
  • Fludarabine is the drug of choice for the majority of patients with CLL.
  • No drug combination is better than single agents.
  • For patients refractory to initial treatment, referral to a clinical trial is the best choice.
  • Other salvage therapy includes retreatment with the same initial agent (chlorambucil or fludarabine) if initial response was observed, or fludarabine for patients refractory to chlorambucil.
  • Promising new approaches include cycle-active agents, nelarabine, biological therapy such as anti-CD52 monoclonal antibody, bone marrow transplantation, including the use of submyeloablative preparative regimens ('minitransplant') to induce graft-versus-leukaemia effect, and gene therapy.
  • Assessment of response to therapy in CLL has been updated by the National Cancer Institute Working Group, and these guidelines are used worldwide for clinical trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Humans. Leukemia, Prolymphocytic / drug therapy. Leukemia, Prolymphocytic / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Semin Hematol. 1987 Oct;24(4):252-6 [3686047.001]
  • [Cites] Blood. 1984 Sep;64(3):642-8 [6466871.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1574-9 [10334546.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2712-6 [3677006.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):671-8 [8097527.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):4-5 [2390480.001]
  • [Cites] Eur J Haematol. 1991 Apr;46(4):202-4 [2015875.001]
  • [Cites] Tumori. 1982 Dec 31;68(6):511-4 [6820205.001]
  • [Cites] Exp Hematol. 1993 Jan;21(1):61-5 [8093352.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):627-9 [7734364.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):697-701 [6589030.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2447-57 [7296493.001]
  • [Cites] Blood. 1988 Dec;72(6):1884-90 [3264192.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Blood. 1989 May 1;73(6):1426-30 [2713486.001]
  • [Cites] Leukemia. 1988 Mar;2(3):157-64 [3347094.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:89-91 [27463486.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Eur J Haematol. 1997 Aug;59(2):82-8 [9293855.001]
  • [Cites] N Engl J Med. 1988 Oct 6;319(14 ):902-7 [2901668.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):457-9 [2464793.001]
  • [Cites] Ann Hematol. 1998 Mar-Apr;76(3-4):101-10 [9619726.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):359-61 [3222145.001]
  • [Cites] Leukemia. 1995 Sep;9(9):1444-9 [7658710.001]
  • [Cites] J Biol Response Mod. 1988 Feb;7(1):97-113 [3373237.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1545-51 [1884021.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5953-8 [2428488.001]
  • [Cites] Am J Hematol. 1981;10(1):9-18 [6973272.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 2:S38-41 [9178837.001]
  • [Cites] Am J Clin Pathol. 1990 Mar;93(3):333-9 [1689938.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1631-5 [9324281.001]
  • [Cites] Br J Haematol. 1986 May;63(1):93-104 [2939873.001]
  • [Cites] Blood. 1982 Nov;60(5):1110-21 [6751436.001]
  • [Cites] J Biol Response Mod. 1985 Jun;4(3):310-23 [3874930.001]
  • [Cites] Neth J Med. 1985;28(3):112-8 [3982571.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):647-51 [9156240.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):983-8 [7707127.001]
  • [Cites] Br J Haematol. 1973 Aug;25(2):171-7 [4726900.001]
  • [Cites] J Mol Med (Berl). 1999 Feb;77(2):266-81 [10023780.001]
  • [Cites] J Clin Oncol. 1984 Aug;2(8):881-91 [6379121.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2313-20 [9667245.001]
  • [Cites] Am J Med. 1991 Feb;90(2):223-8 [1996592.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):812-3 [8094889.001]
  • [Cites] Oncologist. 1999;4(5):352-69 [10551552.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):14-21 [9685175.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):56-62 [9440723.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Am J Med. 1985 Feb;78(2):216-20 [3970047.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):37-43 [8996122.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Haematologica. 1990 Jan-Feb;75(1):75-8 [2338291.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1130-5 [7630184.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1977 Dec;50(6):1049-59 [336116.001]
  • [Cites] Am J Hematol. 1997 Apr;54(4):342 [9092698.001]
  • [Cites] Acta Haematol. 1991;85(1):31-3 [2011927.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):812; author reply 813 [8094888.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):429-32 [3065738.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):74-9 [2416889.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1849-51 [6939479.001]
  • [Cites] Clin Exp Immunol. 1992 Sep;89(3):374-7 [1516254.001]
  • [Cites] Arch Intern Med. 1974 Oct;134(4):721-4 [4415396.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):151-7 [10350343.001]
  • [Cites] Blood. 1987 Mar;69(3):929-36 [3814821.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):48-57 [7237391.001]
  • [Cites] Br J Haematol. 1987 Jan;65(1):23-9 [3468997.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1425-32 [8111709.001]
  • [Cites] Am J Hematol. 1995 Jun;49(2):135-42 [7771465.001]
  • [Cites] Leukemia. 1991 Feb;5(2):150-5 [1673487.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1985-9 [8410123.001]
  • [Cites] Blood. 1990 Apr 1;75(7):1414-21 [2180492.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):813-4 [8094890.001]
  • [Cites] Am J Hematol. 1987 Oct;26(2):179-89 [3116843.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):83-8 [9250791.001]
  • [Cites] Ann Hematol. 1991 Jul;63(1):1-4 [1715191.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):978-80 [6590113.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):467-72 [9172812.001]
  • [Cites] Cancer Treat Rep. 1986 Sep;70(9):1117-20 [3488805.001]
  • [Cites] Am J Med. 1990 Sep;89(3):388-90 [1697447.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):246-50 [2369709.001]
  • [Cites] Cancer. 1973 Mar;31(3):502-8 [4693581.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1104-8 [7850708.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):509-14 [8882965.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 21;85(8):658-62 [8468724.001]
  • [Cites] Am J Hematol. 1992 Sep;41(1):5-12 [1503099.001]
  • [Cites] Br J Haematol. 1997 May;97(2):466-73 [9163617.001]
  • [Cites] Lancet. 1990 Sep 29;336(8718):820 [1698237.001]
  • [Cites] Blood. 1992 Feb 1;79(3):576-85 [1370636.001]
  • [Cites] Br J Haematol. 1986 Jun;63(2):377-87 [3487341.001]
  • [Cites] Oncology. 1985;42(6):350-3 [4069549.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):264-9 [1354412.001]
  • [Cites] Blood. 1990 Apr 1;75(7):1422-5 [2180493.001]
  • [Cites] Hematol Cell Ther. 1996 Aug;38(4):359-60 [8891729.001]
  • [Cites] Recenti Prog Med. 1986 Feb;77(2):100-3 [3715170.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4259-64 [8943862.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2431-48 [7666104.001]
  • [Cites] Br J Haematol. 1986 Mar;62(3):567-75 [3954968.001]
  • [Cites] Clin Lab Haematol. 1988;10(4):391-5 [3250787.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:101-3 [27463489.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1562-9 [1714949.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):433-8 [2784491.001]
  • [Cites] Br J Haematol. 1989 Nov;73(3):334-40 [2690923.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Blood. 1981 Mar;57(3):406-17 [6970050.001]
  • [Cites] Ann Intern Med. 1998 Oct 1;129(7):559-66 [9758577.001]
  • [Cites] Am J Hematol. 1985 May;19(1):63-73 [3845763.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2070-5 [2478221.001]
  • [Cites] Bone Marrow Transplant. 1994 Feb;13(2):217-9 [8205094.001]
  • [Cites] Br J Haematol. 1986 Nov;64(3):469-78 [3466642.001]
  • [Cites] J Natl Cancer Inst. 1990 Sep 5;82(17):1416-20 [2388293.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):81-6 [1904989.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1732-7 [10029603.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1023-6 [9818078.001]
  • [Cites] Am J Hematol. 1992 Sep;41(1):45-9 [1503098.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:139-45 [8097653.001]
  • [Cites] Blood. 1988 May;71(5):1295-8 [3258768.001]
  • [Cites] Ann Intern Med. 1992 Sep 15;117(6):466-9 [1354425.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):120-3 [1713049.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] N Engl J Med. 1992 Oct 8;327(15):1056-61 [1355853.001]
  • [Cites] Hematol Oncol. 1991 Nov-Dec;9(6):315-21 [1748398.001]
  • [Cites] Br J Haematol. 1990 Sep;76(1):45-57 [2223648.001]
  • [Cites] Blood. 1989 Jul;74(1):19-25 [2473795.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2637-40 [3677002.001]
  • [Cites] Eur J Haematol. 1997 Aug;59(2):124-5 [9293862.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2160-6 [8683250.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2216-28 [7931492.001]
  • [Cites] Cancer. 1985 Nov 15;56(10):2369-75 [3899346.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):98-106 [9482531.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1524-9 [6950800.001]
  • [Cites] Cancer. 1978 May;41(5):1664-9 [647620.001]
  • [Cites] Br J Haematol. 1987 Oct;67(2):235-9 [3499930.001]
  • [Cites] Cancer Treat Rep. 1979 Mar;63(3):441-7 [371799.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1225-8 [2428492.001]
  • [Cites] Invest New Drugs. 1987;5(2):207-10 [2443463.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1699-707 [9823944.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1992-2002 [10068672.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1366-76 [7688995.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):121-6 [8641639.001]
  • [Cites] Lancet. 1990 Nov 3;336(8723):1130 [1700245.001]
  • [Cites] Br J Haematol. 1979 Jul;42(3):488-90 [476003.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:93-6 [27463487.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):397-9 [6587931.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):52-60 [8996124.001]
  • [Cites] Eur J Haematol. 1992 May;48(5):266-70 [1644158.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):77-86 [3463362.001]
  • [Cites] Bone Marrow Transplant. 1998 Mar;21(6):627-8 [9580345.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] Am J Hematol. 1987 Nov;26(3):279-84 [3674007.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):897-903 [1737352.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6):695-706 [1361080.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):398-406 [3819805.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;15(3):233-5 [2414021.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):770-6 [2016618.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Nouv Rev Fr Hematol. 1989;31(6):413-5 [2616270.001]
  • [Cites] Br J Haematol. 1991 Oct;79 Suppl 1:30-3 [1931705.001]
  • [Cites] Am J Hematol. 1990 Mar;33(3):189-97 [2405649.001]
  • [Cites] J Clin Oncol. 1986 Feb;4(2):128-36 [3511183.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):433-6 [3065739.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:133-8 [27463495.001]
  • [Cites] Leuk Lymphoma. 1990;2(6):391-7 [27457043.001]
  • [Cites] Leukemia. 1999 Apr;13(4):518-23 [10214856.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] J Natl Cancer Inst. 1987 Jan;78(1):91-4 [3467132.001]
  • [Cites] Eur J Haematol. 1987 Feb;38(2):123-30 [3595807.001]
  • [Cites] Br J Haematol. 1982 Apr;50(4):627-36 [6978147.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):748-58 [8151318.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):733-43 [3282467.001]
  • [Cites] Ann Intern Med. 1993 Jan 15;118(2):114-6 [8416307.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):458-65 [9053466.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1623-32 [7037702.001]
  • [Cites] Haematologica. 1989 Sep-Oct;74(5):481-5 [2511118.001]
  • [Cites] J Clin Invest. 1982 Dec;70(6):1148-56 [6816810.001]
  • [Cites] Leuk Lymphoma. 1993 Jun;10(3):187-93 [8220117.001]
  • [Cites] Acta Haematol. 1991;85(4):209-11 [1853684.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):311-5 [8554226.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):42-59 [9482526.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):833-4 [1697401.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):319-22 [7904047.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):171-2 [1606091.001]
  • (PMID = 10733261.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 236
  •  go-up   go-down


10. Köppler H, Heymanns J, Pandorf A, Weide R: Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma; 2004 May;45(5):911-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
  • The toxicity arid efficacy of the combination bendamustine plus mitoxantrone (BM) was evaluated in 22 patients with advanced chronic lymphocytic leukaemia (CLL).
  • Six out of twenty-two patients were Binet stage B and 16/22 Binet stage C.
  • The number of courses was limited to six and chemotherapy stopped when a complete remission (CR) or partial remission (PR) according to NCI-Criteria was achieved.
  • Six out of twenty-two patients achieved a CR and 13/22 patients a PR resulting in an overall response rate of 86% (19/22 patients).
  • Median time to progression was 10 months (range 4-22) and median survival 39 months (range 6-50).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Bendamustine Hydrochloride. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Nitrogen Mustard Compounds / administration & dosage. Opportunistic Infections / chemically induced. Remission Induction. Survival Analysis

  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15291348.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


11. Hamblin TJ: Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs; 2001;61(5):593-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achieving optimal outcomes in chronic lymphocytic leukaemia.
  • Chronic lymphocytic leukaemia (CLL) is a disease of late middle age and older.
  • The immunophenotype of CLL is sparse surface immunoglobulin, CD5+, CD19+, CD23+, CD79b-, and FMC7-.
  • Most patients have an early stage of disease when diagnosed and perhaps 50% will never progress.
  • This group of patients have a normal life expectancy and do not require treatment beyond reassurance.
  • Intermittent chlorambucil remains the first choice treatment for the majority of patients.
  • Combination chemotherapy offers no advantage.
  • Intravenous fludarabine is probably more effective than chlorambucil, but no trial has yet shown a survival advantage for using it first rather than as a salvage treatment in patients not responding to chlorambucil.
  • It is at least 40 times as expensive as chlorambucil.
  • For patients refractory to both drugs, a variety of options are available.
  • High dose corticosteroids, high dose chlorambucil, CHOP (cyclophosphamide, prednisolone, vincristine and doxorubicin), anti-CD52, anti-CD20 and a range of experimental drugs which are being evaluated in clinical trials.
  • Younger patients should be offered the chance of treatment with curative intent, preferably in the context of a clinical trial.
  • Only time will tell whether some of these patients are cured but it seems unlikely.
  • Standard allogeneic bone marrow transplant is probably too hazardous for most patients, but non-myeloablative regimens hold out the hope of invoking a graft-versus-leukaemia effect without a high tumour-related mortality.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1574-9 [10334546.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Clin Exp Immunol. 1966 Jan;1(1):3-11 [5953036.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2107-14 [9179056.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):4-5 [2390480.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:89-91 [27463486.001]
  • [Cites] Hematol Cell Ther. 1998 Jun;40(3):113-8 [9698219.001]
  • [Cites] Br J Ophthalmol. 2000 Jan;84(1):117 [10691327.001]
  • [Cites] Acta Oncol. 1995;34(4):536-7 [7605666.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1729-35 [2247105.001]
  • [Cites] N Engl J Med. 1988 Oct 6;319(14 ):902-7 [2901668.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):99-104 [9929100.001]
  • [Cites] Leuk Res. 1999 Mar;23(3):277-9 [10071081.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):359-61 [3222145.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):65-74 [9482528.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):983-8 [7707127.001]
  • [Cites] Medicine (Baltimore). 1986 Sep;65(5):339-51 [3091991.001]
  • [Cites] J Clin Oncol. 1984 Aug;2(8):881-91 [6379121.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2313-20 [9667245.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Am J Clin Pathol. 1997 Oct;108(4):378-82 [9322589.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):14-21 [9685175.001]
  • [Cites] Immunol Rev. 1998 Apr;162:247-59 [9602369.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1130-5 [7630184.001]
  • [Cites] J Allergy Clin Immunol. 1996 Apr;97(4):998-1008 [8655897.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1365-74 [8695855.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Blood. 1993 Feb 1;81(3):597-601 [8094016.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):151-7 [10350343.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):437-42 [3065740.001]
  • [Cites] Baillieres Clin Haematol. 1993 Dec;6(4):849-66 [8038493.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1425-32 [8111709.001]
  • [Cites] Am J Hematol. 1995 Jun;49(2):135-42 [7771465.001]
  • [Cites] Clin Lab Haematol. 1997 Jun;19(2):151-2 [9218157.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):813-4 [8094890.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):362-3 [10355587.001]
  • [Cites] Ann Hematol. 1997 Nov-Dec;75(5-6):227-30 [9433380.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):177-88 [8546551.001]
  • [Cites] Am J Med. 1990 Sep;89(3):388-90 [1697447.001]
  • [Cites] Cancer. 1973 Mar;31(3):502-8 [4693581.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1104-8 [7850708.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):509-14 [8882965.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):529-37 [7213576.001]
  • [Cites] Leukemia. 1997 Jan;11(1):170 [9001435.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] Br J Haematol. 1986 Jun;63(2):377-87 [3487341.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):109-13 [9111592.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):242-6 [10589081.001]
  • [Cites] Tumori. 1995 Nov-Dec;81(6):419-23 [8804467.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4259-64 [8943862.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2431-48 [7666104.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1569-73 [1679357.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):27-31 [10634642.001]
  • [Cites] Br J Haematol. 1986 Mar;62(3):567-75 [3954968.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):836-7 [10469479.001]
  • [Cites] Ann Pharmacother. 1992 Jul-Aug;26(7-8):939-47 [1504408.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):433-8 [2784491.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):140-4 [2112977.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):300-1 [7612497.001]
  • [Cites] J Natl Cancer Inst. 1990 Sep 5;82(17):1416-20 [2388293.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):81-6 [1904989.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3209-10 [9738600.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):649-52 [7819085.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):826-8 [8536738.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1112-3 [9734670.001]
  • [Cites] Sangre (Barc). 1997 Jun;42(3):254-6 [9381277.001]
  • [Cites] N Engl J Med. 1992 Oct 8;327(15):1056-61 [1355853.001]
  • [Cites] Novartis Found Symp. 1998;215:200-11; discussion 211-30 [9760581.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Nephrol Dial Transplant. 1996 Nov;11(11):2306-8 [8941597.001]
  • [Cites] Lancet. 1993 Aug 28;342(8870):555 [8102691.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):730-1 [8664199.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):121-6 [8641639.001]
  • [Cites] Concepts Immunopathol. 1987;4:24-41 [2885092.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):677-9 [9531333.001]
  • [Cites] Ann Oncol. 1995 May;6(5):421-33 [7669706.001]
  • [Cites] Am J Pathol. 1928 Jul;4(4):285-292.7 [19969796.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] Baillieres Clin Haematol. 1987 Jun;1(2):449-91 [3322445.001]
  • [Cites] Acta Haematol. 1995;93(2-4):73-9 [7543720.001]
  • [Cites] J Clin Pathol. 1995 Feb;48(2):181-2 [7745121.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Br Med J. 1973 Oct 6;4(5883):23-4 [4585418.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:133-8 [27463495.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):391-8 [9684936.001]
  • [Cites] Am J Hematol. 1995 Apr;48(4):293 [7717386.001]
  • [Cites] Leukemia. 1999 Apr;13(4):518-23 [10214856.001]
  • [Cites] Am J Hematol. 1990 Sep;35(1):32-6 [2202205.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):238-9 [1457584.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):748-58 [8151318.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):733-43 [3282467.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):458-65 [9053466.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1144-50 [9067285.001]
  • [Cites] Br Med J. 1974 Sep 14;3(5932):655-7 [4279123.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Ann Hematol. 2000 Jan;79(1):43-5 [10663621.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2455-7 [10787241.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):311-5 [8554226.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):833-4 [1697401.001]
  • [Cites] Br J Cancer. 1984 May;49(5):547-57 [6722005.001]
  • [Cites] Leuk Lymphoma. 1993 Sep;11(1-2):63-8 [8220155.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):319-22 [7904047.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):117-22 [10052715.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):171-2 [1606091.001]
  • (PMID = 11368285.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 156
  •  go-up   go-down


12. Mukiibi JM, Paul B, Nyirenda CM, Adewuyi JO, Gwanzura C, Mzulu E, Mbvundula EM, Magombo ED, Malata HN: Chronic lymphocytic leukaemia (CLL) in Central Africans. Cent Afr J Med; 2004 Nov-Dec;50(11-12):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia (CLL) in Central Africans.
  • OBJECTIVE: To document the clinical and haematological features of chronic lymphocytic leukaemia (CLL) in Central Africans.
  • The majority of patients (78.7%) had Rai stage III and IV and only seven (9.3%) patients were in stage 0.
  • Of the 32 patients treated with chemotherapy, 25.9% and 59.3% achieved complete or partial remissions respectively.
  • In the untreated group of 43 patients, two refused therapy, four died shortly after diagnosis and 37 were lost to follow up.
  • CONCLUSIONS AND RECOMMENDATIONS: Although the study has disclosed that CLL is not rare in central Africans and its presentations are similar to cases reported in the literature, the majority of patients seek medical treatment late.
  • Optimal therapy is impossible due to lack of chemotherapy and supportive services..Therefore, it is recommended that tertiary referral centers in African health systems should be equipped for better management of CLL patients.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615660.001).
  • [ISSN] 0008-9176
  • [Journal-full-title] The Central African journal of medicine
  • [ISO-abbreviation] Cent Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Zimbabwe
  •  go-up   go-down


13. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic trioxide (As(2)O(3)) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies.
  • Patients received As(2)O(3) 0.25 mg/kg iv and AA 1000 mg iv for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2-6.
  • In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl-2 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment.
  • Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%.
  • The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity.
  • Intracellular depletion of glutathione was not consistently observed during treatment.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


14. Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR: Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med; 2007 Oct;65(9):333-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
  • BACKGROUND: Alemtuzumab (MabCampath) is a monoclonal antibody against CD52, indicated as third-line treatment of chronic lymphocytic leukaemia (CLL).
  • METHODS: To gain insight into the use and complications of alemtuzumab therapy, the alemtuzumab-treated CLL patients in 15 hospitals in the Netherlands were evaluated by means of a questionnaire.
  • RESULTS: In the period from 31 October 2001 until 17 November 2005, 27 patients with CLL or prolymphocytic leukaemia (PLL), RAI stage I to IV, Binet stage A to C, received 32 treatments with alemtuzumab.
  • The time from diagnosis until start of alemtuzumab treatment was 6 +/- 4.5 years (mean +/- SD ).
  • The treatment lasted 11 +/- 7 weeks.
  • Of the treatments, 41% could be administered for the full 12 weeks.
  • Infectious complications occurred in 12 of 32 (38%) treatments: pneumonia (25%; of which one Pneumocystis carini pneumonia and four Aspergillus infections), sepsis (9%; of which one Listeria), herpes zoster (9%), herpes simplex (6%), CMV reactivation (6%), meningitis (3%) and Guillain Barre (3%).
  • CONCLUSION: Treatment with alemtuzumab is often terminated prematurely, leading to a suboptimal treatment effect.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / drug effects. Antigens, Neoplasm / drug effects. Aspergillosis / chemically induced. Drug Evaluation. Drug Resistance, Neoplasm. Glycoproteins / drug effects. Humans. Medical Records. Netherlands. Opportunistic Infections / chemically induced. Pneumonia, Pneumocystis / chemically induced. Remission Induction. Retrospective Studies. Surveys and Questionnaires. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954952.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


15. Bauduer F, Capdupuy C, Renoux M: Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases. Support Care Cancer; 2000 Jul;8(4):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underlying diseases were: multiple myeloma (9 cases), acute myeloid leukaemia (22), lymphoma (14), chronic lymphocytic leukaemia (6), acute lymphoblastic leukaemia (4), myelodysplastic syndromes (3), solid tumours (11), and other (12).
  • Only 15 patients had been admitted for the first time.
  • In 70% of these cases death appeared predictable, as the consequence of refractory or end-stage disease.
  • The percentages of use of therapy tools chosen as indicators were: benzodiazepines 80%; chemotherapy 46%; anti-infectious agents 47%; transfusions 42%; major analgesics 27%; and steroids 40%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Female. Humans. Male. Medical Oncology. Middle Aged. Pain / drug therapy. Prospective Studies. Quality of Health Care

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923770.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


16. Olaniyi JA, Ibijola AA: Richter's syndrome: a case report. Med Princ Pract; 2009;18(2):152-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL PRESENTATION AND INTERVENTION: A 52-year-old male had been diagnosed earlier as having chronic lymphocytic leukaemia (CLL) and treated for 6 months with chlorambucil, although compliance was poor and the patient eventually stopped treatment.
  • The blood and bone marrow smear review, together with fine-needle aspiration cytology of the masses, showed diffuse large cells of non-Hodgkin lymphoma consistent with the Richter's syndrome stage of CLL.
  • There was significant improvement in response to the first 4 cycles of CHOP chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone) instituted, but then there were features of relapse.
  • CONCLUSION: The case report serves to increase awareness and improve the index of suspicion about the terminal phase of CLL and low-grade lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19204436.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Ali R, Ozkalemkaş F, Ozkocaman V, Bülbül-Başkan E, Ozçelik T, Ozan U, Kimya Y, Tunali A: Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukapheresis. Ann Hematol; 2004 Jan;83(1):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukapheresis.
  • We describe the successful management of a 30-year-old woman in the second trimester of her pregnancy with chronic lymphocytic leukemia (CLL) in stage IV by using only leukapheresis.
  • The procedure did not have any significant adverse effect on the patient and the fetus.
  • Seven months after delivery, Richter's syndrome developed in the patient.
  • We conclude that leukapheresis may provide an alternative for palliative treatment to chemotherapy in pregnant patients with CLL.
  • To our knowledge, this is the fourth reported case of CLL in pregnancy, and the first management of CLL during pregnancy with leukapheresis.
  • [MeSH-major] Labor, Obstetric. Leukapheresis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Pregnancy Complications, Neoplastic / therapy






Advertisement